These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20218923)

  • 21. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
    Frey SE; Reyes MR; Reynales H; Bermal NN; Nicolay U; Narasimhan V; Forleo-Neto E; Arora AK
    Vaccine; 2014 Sep; 32(39):5027-34. PubMed ID: 25045825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.
    Puig-Barberà J; Diez-Domingo J; Pérez Hoyos S; Belenguer Varea A; González Vidal D
    Vaccine; 2004 Dec; 23(3):283-9. PubMed ID: 15530669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.
    Della Cioppa G; Vesikari T; Sokal E; Lindert K; Nicolay U
    Vaccine; 2011 Nov; 29(47):8696-704. PubMed ID: 21906647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
    Podda A; Del Giudice G
    Expert Rev Vaccines; 2003 Apr; 2(2):197-203. PubMed ID: 12899571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.
    Banzhoff A; Pellegrini M; Del Giudice G; Fragapane E; Groth N; Podda A
    Influenza Other Respir Viruses; 2008 Nov; 2(6):243-9. PubMed ID: 19453401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B; Neri M; Lepri E; Iorio AM
    Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy.
    Iannazzo S
    J Prev Med Hyg; 2011 Mar; 52(1):1-8. PubMed ID: 21710816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.
    Tsai T; Kyaw MH; Novicki D; Nacci P; Rai S; Clemens R
    Vaccine; 2010 Feb; 28(7):1877-80. PubMed ID: 19969117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
    Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A
    Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
    El Sahly H
    Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.
    Puig-Barberà J; Díez-Domingo J; Varea AB; Chavarri GS; Rodrigo JA; Hoyos SP; Vidal DG
    Vaccine; 2007 Oct; 25(42):7313-21. PubMed ID: 17889411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine.
    Durando P; Iudici R; Alicino C; Alberti M; de Florentis D; Ansaldi F; Icardi G
    Hum Vaccin; 2011; 7 Suppl():29-40. PubMed ID: 21245655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].
    Pérez-Rubio A; Eiros JM
    Rev Esp Quimioter; 2018 Feb; 31(1):43-52. PubMed ID: 29355006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients.
    de Roux A; Marx A; Burkhardt O; Schweiger B; Borkowski A; Banzhoff A; Pletz MW; Lode H
    Vaccine; 2006 Mar; 24(10):1537-42. PubMed ID: 16288937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MF59 adjuvant: the best insurance against influenza strain diversity.
    O'Hagan DT; Rappuoli R; De Gregorio E; Tsai T; Del Giudice G
    Expert Rev Vaccines; 2011 Apr; 10(4):447-62. PubMed ID: 21506643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major.
    Esposito S; D'Angelo E; Daleno C; Peia F; Scala A; Serra D; Mirra N; Galeone C; Principi N
    Vaccine; 2010 Nov; 28(50):7825-8. PubMed ID: 20888873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza control in the 21st century: Optimizing protection of older adults.
    Monto AS; Ansaldi F; Aspinall R; McElhaney JE; Montaño LF; Nichol KL; Puig-Barberà J; Schmitt J; Stephenson I
    Vaccine; 2009 Aug; 27(37):5043-53. PubMed ID: 19559118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.